Genome-wide association study identifies genetic variants which predict the response of bone mineral density to teriparatide therapy.

Teriparatide (TPTD) is an effective treatment for osteoporosis but the individual response to therapy is variable for reasons that are unclear. This study aimed to determine whether the response to TPTD might be influenced by genetic factors. We searched for predictors of the response of bone mineral density (BMD) to TPTD using a two-stage genome-wide association study in 437 patients with osteoporosis from three referral centres. Demographic and clinical data including the response of BMD to treatment at the lumbar spine and hip were extracted from the medical records of each participant. Allelic variation at rs6430612 on chromosome 2, close Genetic factors influence the response to TPTD at the lumbar spine and hip with a magnitude of effect that is clinically relevant. Further studies are required to identify the causal genetic variants and underlying mechanisms as well as to explore how genetic testing for these variants might be implemented in clinical practice.

Informations de copyright

© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: BLL has served on advisory boards and received lecture honoraria from Amgen, UCB, Gideon-Richter, Astellas and Astra-Zeneca. She holds research grants from Novo Nordisk and Amgen. SHR holds research grants from Amgen, Eli Lilly and UCB.